Jul 5, 2022 · NEPC lesions uniquely express delta-like ligand 3 (DLL3) on their cell surface. Taking advantage of DLL3 overexpression, we developed and evaluated lutetium-177 (177 Lu)-labeled DLL3-targeting antibody SC16 (177 Lu-DTPA-SC16) as a treatment for NEPC.

Mar 7, 2025 · To treat and diagnose NEPC effectively, MSK researchers identified a new target: a ligand (molecule) called DLL3. This ligand is especially prominent in NEPC as well as in small cell lung cancer (SCLC), an aggressive form of that disease.

Aug 19, 2022 · Delta-like ligand 3 (DLL3) is overexpressed in many NENs, implicated in tumor progression, and associated with poor clinical outcomes, especially in patients with NEC. DLL3-targeting therapies are currently under clinical investigation, with promising antitumor activity demonstrated to date.

Dec 1, 2024 · Delta-like ligand 3 (DLL3), an inhibitory ligand of Notch receptor, has emerged as a potential target for novel diagnostic and therapeutic strategies in NENs, since overexpression of DLL3 has been associated with tumor progression, poor prognosis and dedifferentiation in …

Feb 14, 2025 · DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers.

Apr 30, 2019 · New data show that >75% of castration-resistant small-cell neuroendocrine prostate cancers (CRPC-NE) express the Notch ligand delta-like protein 3 (DLL3), which can be targeted by the...

May 1, 2020 · Our goal is to develop a PET based molecular imaging agent that can uniquely identify NEPC lesions. Taking advantage of highly specific expression of Delta-like ligand 3 (DLL3) in NEPC lesions, we have developed zirconium-89 labeled immunoPET agent that can specifically identify NEPC lesions.

Jun 2, 2022 · DLL3 is a cell surface protein that is emerging as a promising therapeutic target in NENs including neuroendocrine prostate cancer (NEPC) and small cell lung cancer (SCLC). Our recent study indicated that ̃77% of NEPCs expressed DLL3, with expression in circulating tumor cells being highly concordant with matched biopsies.

Abstract: Treatment-induced neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (CRPC). Using the zirconium-89 (89Zr)-labeled DLL3 targeting antibody SC16 (89Zr-DFO-SC16), we have developed a positron emission tomography (PET) agent to non-invasively identify the presence of DLL3-positive NEPC lesions.

Jul 11, 2024 · Tarlatamab-dlle (Imdelltra) demonstrated a manageable safety profile and early antitumor activity in patients with DLL3-expressing neuroendocrine prostate cancer (NEPC), according to early data...